- ¥155bn
- ¥524bn
- ¥556bn
- 16
- 54
- 44
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.45 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.7% | ||
| Return on Equity | -35.5% | ||
| Operating Margin | -53.57% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 459,267 | 482,732 | 515,952 | 560,035 | 555,544 | 316,569 | 349,716 | 3.54% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -5.65 | +3.64 | +16.94 | -13.55 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sumitomo Pharma Co Ltd, formerly Sumitomo Dainippon Pharma Co Ltd, is a Japan-based pharmaceutical company. The Company operates its business through four segments. The Japan segment is engaged in the manufacture, purchase, and sale of ethical drugs. The North American segment is engaged in the manufacture, purchase, and sale of ethical drugs and conducts research and development in the areas of oncology, urology, respiratory disease, and regenerative cell medicine. The China segment is engaged in the manufacture (small packaged products) and sale of ethical pharmaceuticals. The Overseas Others segment is engaged in the manufacture and sale of ethical pharmaceuticals in Europe. The segment also purchase and sell ethical pharmaceuticals in Southeast Asia and Taiwan, as well as provide information and collection activities for the Company's products. Other business includes manufacturing, purchasing, and sales of food ingredients, food additives and chemical product materials.
Directors
- Masayo Tada CHM (76)
- Hiroshi Nomura PRE (63)
- Toru Kimura CSO (60)
- Hitoshi Odagiri SME (64)
- Yoshiharu Ikeda MEO (63)
- Hiroyuki Baba MEO
- Hideyuki Harada MEO
- Shigeyuki Nishinaka MEO (55)
- Takuya Taguchi DSL
- Patricia Andrews EXO (63)
- Atsuko Higuchi EXO
- Koichi Kozuki EXO
- Antony Loebel EXO
- Yumi Sato EXO
- Isao Shimizu EXO
- Kenji Ueno EXO
- Saeko Arai IND (57)
- Yutaka Atomi IND (76)
- Nobuhiro Endo IND (67)
- Minoru Usui IND (66)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 14th, 1897
- Public Since
- May 16th, 1949
- No. of Shareholders
- 32,494
- No. of Employees
- 6,250
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange- Shares in Issue
- 397,291,102
- Address
- 2-6-8, Dosho-machi, Chuo-ku, OSAKA-SHI, 541-0045
- Web
- https://www.sumitomo-pharma.co.jp/
- Phone
- +81 662035321
- Auditors
- KPMG AZSA LLC
Latest News for 4506
Upcoming Events for 4506
Full Year 2024 Sumitomo Pharma Co Ltd Earnings Release
Sumitomo Pharma Co Ltd Annual Shareholders Meeting
Q1 2025 Sumitomo Pharma Co Ltd Earnings Release
Similar to 4506
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 19:20 UTC, shares in Sumitomo Pharma Co are trading at ¥389. This share price information is delayed by 15 minutes.
Shares in Sumitomo Pharma Co last closed at ¥389 and the price had moved by -53.47% over the past 365 days. In terms of relative price strength the Sumitomo Pharma Co share price has underperformed the Nikkei 225 Index by -64.98% over the past year.
The overall consensus recommendation for Sumitomo Pharma Co is Sell. You can view the full broker recommendation list by unlocking its StockReport.
The Sumitomo Pharma Co dividend yield is 1.8% based on the trailing twelve month period.
Last year, Sumitomo Pharma Co paid a total dividend of ¥7, and it currently has a trailing dividend yield of 1.8%. We do not have any data on when Sumitomo Pharma Co is to next pay dividends.
We do not have data on when Sumitomo Pharma Co is to next pay dividends. The historic dividend yield on Sumitomo Pharma Co shares is currently 1.8%.
To buy shares in Sumitomo Pharma Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥389, shares in Sumitomo Pharma Co had a market capitalisation of ¥155bn.
Here are the trading details for Sumitomo Pharma Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4506
Based on an overall assessment of its quality, value and momentum Sumitomo Pharma Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sumitomo Pharma Co is ¥346. That is 11.13% below the last closing price of ¥389.
Analysts covering Sumitomo Pharma Co currently have a consensus Earnings Per Share (EPS) forecast of -¥465 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sumitomo Pharma Co. Over the past six months, its share price has underperformed the Nikkei 225 Index by -34.03%.
As of the last closing price of ¥389, shares in Sumitomo Pharma Co were trading -18.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sumitomo Pharma Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥389.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sumitomo Pharma Co's management team is headed by:
- Masayo Tada - CHM
- Hiroshi Nomura - PRE
- Toru Kimura - CSO
- Hitoshi Odagiri - SME
- Yoshiharu Ikeda - MEO
- Hiroyuki Baba - MEO
- Hideyuki Harada - MEO
- Shigeyuki Nishinaka - MEO
- Takuya Taguchi - DSL
- Patricia Andrews - EXO
- Atsuko Higuchi - EXO
- Koichi Kozuki - EXO
- Antony Loebel - EXO
- Yumi Sato - EXO
- Isao Shimizu - EXO
- Kenji Ueno - EXO
- Saeko Arai - IND
- Yutaka Atomi - IND
- Nobuhiro Endo - IND
- Minoru Usui - IND